Skip to main content
Fig. 2 | BMC Infectious Diseases

Fig. 2

From: Assessment of an optimized manufacturing process for inactivated quadrivalent influenza vaccine: a phase III, randomized, double-blind, safety and immunogenicity study in children and adults

Fig. 2

Hemagglutinin-inhibition antibody responses in adults aged 18–49 years in the per-protocol immunogenicity cohort. a = GMT, geometric mean titer; b = SCR, seroconversion rate; d= SPR, seroprotection rate; IIV4-I, quadrivalent inactivated influenza vaccine manufacturing by investigational process; IIV4, licensed quadrivalent inactivated influenza vaccine; CI, confidence interval; n, number of subjects in the per-protocol cohort

Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us